Verastem is a highly asymmetric oncology bet: newly commercial in rare ovarian cancer, potentially transformative in KRAS G12D tumors, but exposed to binary trial risk and dilution.
Verastem, Inc. (operating commercially as Verastem Oncology) is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted small-molecule drugs to treat patients diagnosed with RAS/MAPK pathway-driven cancers.[1, 2] This molecular pathway regulates cell growth and survival, and its dysregulation is a primary driver in numerous highly prevalent human malignancies.[1, 3] Verastem transitioned from a clinical-stage research entity into a commercial-stage enterprise following the U.S. Food and Drug Administration (FDA) accelerated approval of its lead therapeutic combination on May 8, 2025.[1, 4]
The company generates revenue exclusively through the commercial sale of its sole approved product, the AVMAPKI FAKZYNJA CO-PACK, within the United States.[5] Geographically, the United States is the company’s only active revenue-producing region, though management is actively preparing regulatory pathways to support geographic expansion into Europe and Japan.[5] The company does not currently generate revenue from licensing milestone payments, having completed the sale of its previous commercial asset, COPIKTRA, and its associated milestones to Secura Bio in fiscal year 2024.[6]
Verastem's core product, the AVMAPKI FAKZYNJA CO-PACK, is a co-packaged combination of avutometinib capsules (an oral RAF/MEK clamp) and defactinib tablets (an oral, selective focal adhesion kinase inhibitor).[4, 7] This combination represents a novel-novel pairing designed to deliver a synergistic, multi-node blockade of the RAS/MAPK signaling pathway.[1, 6] The primary customer base consists of gynecologic oncologists and medical oncologists who practice in both academic medical centers and community oncology networks.[6] To manage the distribution of this specialty therapeutic regimen, Verastem has partner-contracted with Onco360 as its exclusive specialty pharmacy distributor.[8]
The company's most important end market is the therapeutic segment for recurrent low-grade serous ovarian cancer (LGSOC).[7, 9] LGSOC is a rare, insidious, and persistent form of ovarian cancer that is biologically distinct from high-grade serous ovarian cancer (HGSOC).[9] It predominantly affects younger women (with bimodal diagnostic peaks between ages 20–30 and 50–60) and is characterized by high recurrence rates and poor sensitivity to standard-of-care systemic chemotherapies.[9]
Clinicians select Verastem's CO-PACK over alternative standard options because it is the first and only FDA-approved therapy specifically indicated to treat adult patients with recurrent, KRAS-mutated LGSOC who have received at least one prior systemic therapy.[1, 10] Traditional therapeutic alternatives, which include standard chemotherapies and hormone therapies, have historically delivered poor objective response rates ranging from 6% to 26% and limited progression-free survival.[11, 12] While off-label MEK inhibitors have been used in this segment, they suffer from rapid treatment failure due to compensatory activation of upstream RAF kinases and FAK-mediated resistance pathways.[1, 13] The CO-PACK’s unique dual mechanism of action overcomes these bypass resistance pathways, providing superior and more durable anti-tumor activity.[1, 13]
Verastem's strategic value and revenue trajectory are anchored in its small-molecule oncology portfolio, which targets critical nodes of the RAS/RAF/MEK/ERK (MAPK) signaling pathway.[1, 3] The lead commercial asset, the AVMAPKI FAKZYNJA CO-PACK, represents a combination of two distinct therapeutic mechanisms.[4, 7] Avutometinib (AVMAPKI, formerly VS-6766) is an oral RAF/MEK clamp.[12, 13] Unlike traditional, first-generation MEK-only inhibitors, which trigger a compensatory reactivation of MEK by upstream RAF kinases, avutometinib induces inactive complexes of MEK with ARAF, BRAF, and CRAF.[13, 14] This mechanism blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK, creating a more complete blockade of the MAPK cascade.[13, 14] Defactinib (FAKZYNJA) is an oral, selective Focal Adhesion Kinase (FAK) inhibitor.[1, 13] FAK is a cytoplasmic tyrosine kinase that acts as a major mediator of cellular adhesion, survival, and drug resistance; its activation is a known bypass escape mechanism when the MAPK pathway is pharmacologically blocked.[1] Co-administering defactinib alongside avutometinib provides a simultaneous dual-node blockade that prevents tumor escape and resistance.[1, 13]
The company's pipeline is led by VS-7375, a highly selective oral KRAS G12D dual "ON/OFF" inhibitor licensed from GenFleet Therapeutics in January 2025.[2, 15] Standard KRAS inhibitors are restricted to binding the protein in either its active (ON) GTP-bound state or its inactive (OFF) GDP-bound state.[3, 15] In contrast, VS-7375 binds both conformation states, enabling a more robust and continuous shutdown of downstream oncogenic signaling.[3, 15] In mid-2026, Verastem rebranded its clinical strategy to initiate three Phase 2 registration-directed trials under the "VS-7375 TARGET-D" clinical program:
* TARGET-D 201: Dosed its first patient on June 16, 2026, to evaluate VS-7375 (900 mg once daily) as a monotherapy and in combination with cetuximab for second-line metastatic pancreatic ductal adenocarcinoma (PDAC), alongside a frontline combination cohort.[5, 15]
* TARGET-D 202: Evaluates VS-7375 (900 mg once daily) in advanced non-small cell lung cancer (NSCLC) patients with one to two prior lines of systemic therapy.[3, 5]
* TARGET-D 203: Evaluates VS-7375 (900 mg once daily) as a monotherapy and combined with EGFR inhibitors (cetuximab or panitumumab) in previously treated colorectal cancer (CRC), alongside frontline chemotherapy combination cohorts in metastatic CRC.[5]
Verastem's economic moat is characterized by high clinical switching costs, regulatory exclusivities, and protected intellectual property, creating significant barriers to entry for potential competitors.
Clinical switching costs represent a formidable commercial moat in oncology.[9] Once a patient diagnosed with recurrent LGSOC is stabilized on the CO-PACK, physicians are highly hesitant to transition that patient to alternative therapies.[6, 9] This reluctance is reinforced by the durable efficacy profile demonstrated by the combination.[9] Long-term data from the Phase 2 RAMP 201 trial presented at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting showed a median duration of response (mDoR) of 31.1 months and a median progression-free survival (mPFS) of 19.6 months in patients with KRAS-mutated disease.[9] With 52% of KRAS-mutated patients remaining on therapy for over one year, Verastem secures highly predictable, long-duration recurring revenue per active patient, which deters market entry by off-label competitors.[9]
Regulatory exclusivity and orphan drug protections form a strong legal moat.[13] The FDA’s accelerated approval of the CO-PACK in recurrent KRAS-mutated LGSOC, supported by its Breakthrough Therapy Designation and Orphan Drug Designation, provides statutory market exclusivity and fast-track developmental support.[7, 13] A fast-follower generic cannot enter the market without replicating extensive, multi-year clinical trials.[13] Verastem is actively defending this position by executing RAMP 301, an international Phase 3 confirmatory trial comparing the CO-PACK directly against standard chemotherapy or hormonal therapy.[1, 16]
Furthermore, Verastem's exclusive licensing agreement with GenFleet Therapeutics for VS-7375 provides sole development and commercialization rights in all global territories outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan).[2, 15] This protects the company's long-term pipeline value by preventing international competitors from accessing this dual ON/OFF KRAS G12D inhibitor.[3, 15]
The addressable market for Verastem spans both its commercial niche in LGSOC and several highly prevalent KRAS G12D-mutated solid tumor indications.
LGSOC is a rare disease, with an estimated 6,000 to 8,000 women in the United States and roughly 80,000 women globally currently living with the condition.[9] Approximately 30% of these patients possess a documented KRAS mutation.[9] Verastem has established a wholesale acquisition price of $48,500 per 28-day regimen of the CO-PACK.[8]
Assuming a full 12-month course of therapy, the gross therapeutic cost per compliant patient is approximately $632,000 annually. For the immediate U.S. target population of roughly 1,800 to 2,400 KRAS-mutated LGSOC patients, this pricing yields a total addressable market of $1.1 billion to $1.5 billion annually.[9] If Verastem successfully leverages the ongoing Phase 3 RAMP 301 trial to expand its label regardless of KRAS mutation status, the addressable U.S. LGSOC market would widen to cover all 6,000 to 8,000 patients, representing a potential $3.8 billion to $5.0 billion annual market opportunity.[1, 9] Globally, the broader ovarian cancer therapeutic market across the seven major markets (7MM) was valued at $3.3 billion in 2022 and is projected to expand to $4.1 billion by 2031, with the U.S. consistently representing 58% of total global spend.[4]
| Indication / Clinical Asset | US Target Population (Annual Incidence) | G12D Mutation Prevalence (%) | Implied G12D Patient Volume (Annual) | Status / Current Milestone |
|---|---|---|---|---|
| Recurrent LGSOC / CO-PACK | 6,000 - 8,000 (Prevalence) [9] | 30.0% [9] | 1,800 - 2,400 [9] | Approved May 2025; Phase 3 confirmatory RAMP 301 readout in mid-2027 [4, 5] |
| Pancreatic Cancer / VS-7375 | ~64,000 [2, 15] | 37.0% - 40.0% [3, 15] | 23,680 - 25,600 [3, 15] | Phase 2 TARGET-D 201 trial initiated June 2026; FDA Fast Track granted [5, 15] |
| Non-Small Cell Lung / VS-7375 | ~160,000 [3] | 5.0% [3] | ~8,000 [3] | Phase 2 TARGET-D 202 trial initiated; FDA Fast Track granted June 2026 [3, 5] |
| Colorectal Cancer / VS-7375 | ~150,000 [2, 15] | 12.5% - 15.0% [3, 15] | 18,750 - 22,500 [3, 15] | Phase 2 TARGET-D 203 trial initiated mid-2026 [5] |
The pipeline expansion into KRAS G12D target markets significantly increases Verastem’s commercial opportunity. The KRAS G12D mutation represents the single most prevalent KRAS mutation in human cancers, accounting for approximately 26% of all mutated KRAS solid tumors.[3, 15] The G12D mutation is highly prevalent in pancreatic ductal adenocarcinoma (40% of cases), colorectal cancer (15%), endometrial cancer (8%), biliary tract cancer (7%–15%), and non-small cell lung cancer (5%).[3, 15] In the United States alone, over 8,000 patients are diagnosed annually with KRAS G12D-mutated NSCLC.[3] Because no FDA-approved therapies exist that specifically target the KRAS G12D mutation, the TARGET-D clinical program addresses a massive, high-unmet-need multi-billion dollar market.[3, 15]
In its core recurrent LGSOC market, Verastem is holding a dominant commercial position.[6, 10] Traditional therapy is limited to non-targeted systemic chemotherapies and hormone therapies, which exhibit poor clinical efficacy, with progression-free survival ranging from 7.2 to 13.0 months.[12, 14] Verastem's CO-PACK significantly outperforms these historical baselines, demonstrating an objective response rate of 44% in KRAS-mutated patients and a median progression-free survival of 19.6 months.[9, 11]
While first-generation MEK-only inhibitors are occasionally used off-label, their efficacy is capped by rapid drug resistance and poor tolerability profiles.[13] Verastem is solidifying its market-leading position through the international Phase 3 confirmatory RAMP 301 trial.[1, 16] Success in this trial, with a topline readout expected in mid-2027, will act as a major catalyst to expand the label to all recurrent LGSOC patients, regardless of mutation status, preemptively blocking potential late-stage competitors.[1, 5]
In the highly competitive KRAS G12D oncology space, Verastem is gaining ground due to clinical and safety differentiators:
* Bristol Myers Squibb / Mirati Therapeutics (MRTX1133): MRTX1133 was once considered a major competitive threat as a selective G12D inhibitor.[17] However, the program was terminated in March 2025 due to "formulation challenges" and poor oral bioavailability (under 3%), leaving the selective G12D monotherapy landscape open.[17]
* Revolution Medicine (Daraxonrasib / RMC-6236): RMC-6236 is a pan-RAS tri-complex inhibitor that represents the primary clinical competitor in RAS-mutant cancers.[18, 19] At ASCO 2026, daraxonrasib demonstrated positive survival trends in pre-treated pancreatic cancer, achieving a median overall survival of 13.2 months compared to 6.7 months for chemotherapy.[18]
While Revolution Medicine holds a head start in clinical timelines, Verastem’s VS-7375 stands out as a highly selective oral G12D dual ON/OFF inhibitor.[3, 15] Efficacy data from GenFleet Therapeutics’ clinical trials in China for VS-7375 (known as GFH375) showed a 91.5% tumor reduction rate and a 96.7% disease control rate in advanced pancreatic cancer, with a low treatment discontinuation rate of just 4% due to adverse events.[2] This suggests that VS-7375 possesses a superior therapeutic index and lower toxicity profile compared to pan-RAS inhibitors, which are often limited by skin rash and gastrointestinal toxicity.[2, 20]
Verastem reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026, on May 7, 2026.[5]
The company recorded net product revenue of $18.7 million from the commercial sales of its AVMAPKI FAKZYNJA CO-PACK, up from zero in the first quarter of fiscal year 2025, during which the company had not yet commercialized any assets.[5] Although this represents rapid commercial scaling, the $18.7 million in product revenue missed consensus Wall Street expectations of $21.5 million by 13%, indicating a slower-than-expected commercial ramp in the early launch phase.[21]
GAAP net loss for the first quarter of 2026 was $36.6 million, or -$0.37 per basic share, compared to a GAAP net loss of $52.1 million, or -$0.96 per basic share, in the first quarter of fiscal year 2025.[5] This per-share loss beat the consensus analyst expectation of -$0.47 per share, representing a 21% positive surprise on statutory losses.[21] For the first quarter of 2026, the non-GAAP adjusted net loss was $42.7 million, or -$0.43 per basic share, compared to a non-GAAP adjusted net loss of $42.9 million, or -$0.79 per basic share, in the prior-year quarter.[5] The non-GAAP adjusted EPS of -$0.43 beat the consensus estimate of -$0.47 by 8.51%, driven by disciplined cost-management strategies and favorable research and development spending timing.[22, 23]
| Consolidated Income Statement Metric | Q1 2026 Actual ($ in thousands) | Q1 2025 Actual ($ in thousands) | YoY Change (%) |
|---|---|---|---|
| Net Product Revenue | $18,671 | $0 | N/A [5] |
| Total Revenue | $18,671 | $0 | N/A [5] |
| Cost of Sales | $3,117 | $0 | N/A [5] |
| Research & Development Expenses | $38,152 | $29,150 | +30.9% [5] |
| Selling, General & Admin Expenses | $22,299 | $15,044 | +48.2% [5] |
| Total Operating Expenses | $63,568 | $44,174 | +43.9% [5] |
| Operating Loss | ($44,897) | ($44,174) | +1.6% [5] |
| Interest Income | $1,297 | $960 | +35.1% [5] |
| GAAP Net Loss | ($36,591) | ($52,103) | -29.8% [5] |
| GAAP EPS (Basic) | ($0.37) | ($0.96) | -61.5% [5] |
| GAAP EPS (Diluted) | ($0.46) | ($0.96) | -52.1% [5] |
| Non-GAAP Adjusted Net Loss | ($42,680) | ($42,928) | -0.6% [5] |
| Non-GAAP Adjusted EPS (Basic) | ($0.43) | ($0.79) | -45.6% [5] |
The rise in total operating expenses to $63.6 million in Q1 2026 was driven by higher clinical development and commercialization costs.[5] Cost of sales was $3.1 million, which includes $2.772 million for product cost of sales and $279,000 for intangible asset amortization.[5]
R&D expenses rose 31% to $38.2 million, driven by higher clinical trial costs, investigator fees, drug manufacturing, and contract research organization (CRO) fees associated with Phase 2 trials.[5] This was partially offset by a VS-7375 program option fee paid to GenFleet in the first quarter of 2025.[5] SG&A expenses rose 48% to $22.3 million, driven by higher commercial operations and personnel costs to support the ongoing launch of the CO-PACK.[5]
Verastem ended the first quarter of 2026 with cash, cash equivalents, and investments of $181.7 million, down from $205.0 million as of December 31, 2025.[5] On a pro forma basis, taking into account the net proceeds of $29.4 million from expiring cash warrants exercised in January 2026, the cash balance was $234.4 million at year-end 2025.[6]
The company's basic share count used for basic EPS calculations in Q1 2026 was 98.292 million shares, compared to 54.173 million shares in the prior-year period.[5] The basic shares outstanding reported on the ticker is approximately 87.87 million shares.[24]
During the earnings materials, Verastem management did not provide formal quantitative revenue guidance for the remainder of fiscal year 2026.[25] However, management reiterated that its existing cash position of $181.7 million, supported by ongoing product revenues, is expected to extend the cash runway into the first half of 2027.[5]
Management emphasized that this runway provides sufficient capital to fund operations through several key clinical readouts without immediate financing pressure.[25] The executive team also highlighted the appointment of Daniel Lyons as Chief Commercial Officer to lead the next phase of commercial growth, bringing commercialization expertise from his previous role at SpringWorks Therapeutics.[5]
The first quarter of 2026 earnings announcement had a negative impact on the stock price. In the week following the release, Verastem's stock fell 18% to $4.89, driven by investor concerns over the 13% revenue miss.[21]
Analysts subsequently lowered their consensus revenue estimates for fiscal year 2026 from $114.9 million to $106.2 million.[21] Despite the lower revenue estimates, analysts upgraded their near-term EPS forecasts, narrowing the expected annual loss per share from -$1.71 to -$1.60 on better cost management.[21]
Wall Street sentiment remains optimistic, with 9 analysts maintaining a unanimous "Buy" consensus rating and no "Hold" or "Sell" recommendations.[26, 27] Following the earnings print, the average 12-month price target remained stable, ranging from $14.00 to $18.90, with a consensus average of $16.00 to $16.32.[28, 29]
To evaluate Verastem's intrinsic value, investors should focus on several key financial and valuation drivers rather than near-term earnings multiples.
The company's historical five-year annualized sales growth is negative, showing a decline of 20% per year due to its pre-revenue transition period.[21] However, following the launch of the CO-PACK, revenue growth is accelerating.[5] Analyst consensus projects a 114% revenue increase over the next 12 months, with fiscal year 2026 sales expected to reach $106.2 million.[21] This projected growth rate is significantly higher than the average annual revenue growth rate of 22% for the broader biotechnology industry.[21]
Verastem currently has a market capitalization of approximately $335 million to $366 million, with 87.87 million shares outstanding (weighted average shares outstanding for EPS calculation was 98.29 million in Q1 2026).[5, 24, 30] Based on trailing twelve-month product revenue, the stock trades at a price-to-sales (P/S) multiple of 5.96x.[30] Traditional price-to-earnings (P/E) multiples are not applicable (valued at "NM") because of the company's net loss of $209.5 million in fiscal year 2025 and ongoing cash burn.[6, 24]
The enterprise value (EV) is calculated as:
$EV = \text{Market Cap} + \text{Total Debt} - \text{Cash}$
Using a market cap of $366.43 million, total debt of $85.48 million, and cash of $181.68 million, Verastem's enterprise value is $270.23 million, which translates to a low EV-to-Sales multiple relative to its near-term growth outlook.[24]
The investment thesis for Verastem is subject to several risks across regulatory, clinical, commercial, and financial channels.
The commercial ramp of the AVMAPKI FAKZYNJA CO-PACK is still in its early stages.[5] The Q1 2026 revenue miss of 13% suggests that converting LGSOC patients to this expensive, $48,500 monthly regimen may face reimbursement hurdles, physician inertia, or insurance authorization delays.[8, 21]
The transition of commercial leadership to Daniel Lyons introduces execution risk; any disruption in the company’s commercial strategy could delay the timeline to self-sustainability, which management previously targeted for the second half of 2026.[5, 31]
The oncology sector is highly competitive and rapidly evolving.[18] In the KRAS G12D space, Revolution Medicine is the clear leader, with its pan-RAS tri-complex inhibitor (RMC-6236) already demonstrating strong survival benefits at ASCO 2026.[18]
If Revolution Medicine or another competitor establishes a superior efficacy or safety profile in pancreatic, non-small cell lung, or colorectal cancers, Verastem's VS-7375 TARGET-D program could struggle to capture meaningful market share.[5, 18]
Because the CO-PACK’s commercial approval in recurrent LGSOC was granted under the FDA's accelerated pathway, its long-term market access is contingent on the successful completion of the confirmatory Phase 3 RAMP 301 trial.[7, 14] A failure of RAMP 301 (topline readout expected in mid-2027) would likely result in the FDA withdrawing its commercial approval, which would destroy Verastem's primary source of revenue.[5, 7]
Additionally, the CO-PACK is associated with several severe toxicities, including ocular disorders, serious skin reactions, hepatotoxicity, and rhabdomyolysis.[9] These toxicities require routine clinical monitoring, which could restrict real-world patient compliance and limit market adoption.[9, 20]
Verastem continues to burn cash, reporting a GAAP net loss of $36.6 million in the first quarter of 2026.[5] Its cash runway extends only into the first half of 2027, which guarantees that the company will need to raise additional capital over the next 12 months, likely through dilutive equity offerings or debt financing.[5]
The risk of shareholder dilution is high. At the 2026 annual meeting, stockholders approved an amendment to increase the share pool of the 2021 Equity Incentive Plan by 12,000,000 shares and the 2018 Employee Stock Purchase Plan by 5,000,000 shares, representing an estimated potential dilution of 18.1%.[32]
The biopharmaceutical industry is highly sensitive to changes in healthcare policy and drug pricing regulations. Any policy changes that restrict the pricing power of specialty oncology medications could compress Verastem's gross margins, which currently stand at 85.13%.[24]
Additionally, the company carries $73.12 million in long-term debt, which exposes its balance sheet to interest rate fluctuations and increases its refinancing risk.[5]
The 5-year scenario analysis models Verastem's valuation trajectory through 2031. The modeling is anchored on Verastem's current weighted average share count of 98.29 million, a baseline share price of $4.01, and a starting annualized product revenue run-rate of approximately $75.0 million (derived from Q1 2026 net product sales of $18.7 million).[5, 29]
The exit valuation is calculated using standard biotechnology multiples applied to Year 5 revenues and projected net profits. Dilution is modeled to reflect the company's expected cash burn and the 18.1% dilution overhang from approved equity incentive pools.[5, 32]
The High Case assumes the commercial rollout of the CO-PACK in recurrent LGSOC accelerates globally, capturing a 35% market share of the U.S. and European target populations.[5, 9] It also assumes the Phase 3 RAMP 301 confirmatory trial meets its primary endpoint in mid-2027, allowing for a label expansion to treat patients regardless of their KRAS mutation status.[5, 7]
Simultaneously, the TARGET-D Phase 2 trials for VS-7375 deliver exceptional efficacy and safety data, leading to accelerated FDA approval in second-line pancreatic and NSCLC by 2029.[3, 5] These approvals allow Verastem to tap into the large KRAS G12D mutation market, which has more than 8,000 NSCLC patients diagnosed annually in the U.S. alone.[3]
The Base Case assumes steady commercial execution of the CO-PACK in recurrent LGSOC, capturing approximately 15% of the target patient population in the U.S..[9] The RAMP 301 trial is successful, confirming the accelerated approval, but international expansion is slow.[5, 7]
VS-7375 is approved as a second-line therapy for metastatic pancreatic cancer, but faces competition from Revolution Medicine's daraxonrasib in the broader solid tumor and first-line settings, limiting its market share.[5, 18]
The Low Case assumes a worst-case clinical and regulatory scenario. The Phase 3 RAMP 301 confirmatory trial fails to meet its primary endpoint in mid-2027, prompting the FDA to withdraw its accelerated approval for the CO-PACK in recurrent LGSOC.[5, 7] This completely stops the company's product sales.[5]
Concurrently, the TARGET-D clinical program for VS-7375 is terminated after showing unexpected Grade 3 hepatotoxicity and failing to show a survival advantage over competitor therapies.[3, 5]
The probability-weighted target price is calculated as:
$\text{Weighted Price} = (0.25 \times \$44.44) + (0.50 \times \$13.33) + (0.25 \times \$0.08) = \$11.11 + \$6.67 + \$0.02 = \$17.80 \text{ USD}$
This probability-weighted target of $17.80 USD implies a potential upside of 343.9% over the next five years, which is in line with current analyst price targets.[28, 29]
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $800.0M [3, 5] | 25.0% / $200.0M Net | 7.5x P/S or 30.0x P/E | $4.01 [29] | $44.44 USD [5] | 1,008.2% | 61.8% | 25.0% |
| Base Case | $400.0M [5, 9] | 20.0% / $80.0M Net | 5.0x P/S or 25.0x P/E | $4.01 [29] | $13.33 USD [5] | 232.4% | 27.2% | 50.0% |
| Low Case | $15.0M [6] | -100.0% / -$15.0M Net | 1.0x P/S | $4.01 [29] | $0.08 USD [5, 32] | -98.0% | -54.3% | 25.0% |
| Weighted | N/A | N/A | N/A | $4.01 [29] | $17.80 USD | 343.9% | 34.7% | 100.0% |
HIGHLY ASYMMETRIC OPTION
This qualitative scorecard evaluates Verastem across ten key dimensions, analyzing its commercial, financial, and strategic positioning.
The management alignment rating is 4 out of 10. CEO Daniel Paterson directly owns 0.26% to 0.30% of outstanding shares, which represents a low personal stake relative to peer biotechnology executives.[33] Additionally, insider trading records indicate that management has been a consistent net seller of stock, with Paterson selling 10,321 shares in January 2026 and executing further sales in February and May 2026.[24, 33, 34]
Furthermore, the board's reliance on equity incentive programs contributed to the highly dilutive 18.1% potential shareholder dilution approved at the 2026 annual meeting, suggesting that management’s interests may not be fully aligned with long-term shareholders.[32]
The revenue quality rating is 6 out of 10. Verastem's revenue consists entirely of product sales of its approved CO-PACK, which represents a higher-quality cash flow stream than clinical-stage licensing milestones.[5]
However, because this commercial indication was approved under the FDA's accelerated pathway, the entire revenue stream carries structural regulatory risk and is dependent on the binary outcome of the Phase 3 RAMP 301 confirmatory trial.[7, 14]
The market position rating is 7 out of 10. Verastem holds a strong, first-mover advantage in recurrent LGSOC as the first and only FDA-approved therapy specifically indicated for the KRAS-mutated segment.[1, 10]
However, in the broader solid tumor markets (pancreatic, NSCLC, and CRC), Verastem is an underdog to larger oncology companies, most notably Revolution Medicine, which holds a head start in clinical timelines.[5, 18]
The growth outlook rating is 8 out of 10. Verastem is well-positioned for strong near-term growth, driven by planned geographic expansion into Europe and Japan, and clinical trials to expand its label to all recurrent LGSOC patients.[5]
Additionally, the TARGET-D clinical program for VS-7375 addresses the highly prevalent KRAS G12D mutation, which offers significant long-term commercial upside.[3, 5]
The financial health rating is 5 out of 10. The company holds a solid cash balance of $181.7 million as of March 31, 2026, which is supported by its ongoing product revenues.[5]
However, this is offset by its high cash burn rate (reporting a GAAP net loss of $36.6 million in Q1 2026), which limits its cash runway to the first half of 2027 and guarantees the need for dilutive equity or debt financing within the next 12 months.[5]
The business viability rating is 6 out of 10. The commercial launch of the CO-PACK has validated Verastem's clinical and commercial capabilities, and the dual-action clamp approach represents a highly differentiated strategy.[1, 6]
However, because the cash runway ends in early 2027 and long-term viability depends on the binary outcome of the Phase 3 RAMP 301 trial in mid-2027, the business model remains highly speculative and sensitive to clinical execution.[5]
The capital allocation rating is 5 out of 10. The company's decision to license VS-7375 from GenFleet Therapeutics in January 2025 was a highly opportunistic, low-cost move that significantly enhanced its pipeline.[2, 15]
However, this is offset by its history of high shareholder dilution and option repricing programs, which represent a high cost of capital.[32, 35]
The analyst sentiment rating is 9 out of 10. Wall Street is highly bullish on Verastem's prospects, with analysts maintaining a unanimous "Buy" consensus rating and no hold or sell recommendations.[26, 27]
The consensus 12-month average price target of $16.00 to $16.32 represents a significant potential upside of over 300% from current trading levels.[28, 29]
The profitability rating is 2 out of 10. Verastem remains highly unprofitable, reporting a net loss of $209.5 million in fiscal year 2025 and a net loss of $36.6 million in the first quarter of 2026.[5, 6]
Its return on equity (ROE) is deeply negative, ranging from -663.19% to -1,480.15% because of its high clinical R&D expenses and pre-revenue history.[26, 30]
The track record rating is 3 out of 10. Verastem has a poor history of shareholder value creation. Over the past decade, its share price has declined from over $100 per share in 2013 to approximately $4.00 per share.[36]
This historical decline reflects a long cycle of product development delays, asset sales, and heavy equity dilution.[6, 32, 36]
The blended qualitative score is calculated as the average of the ten dimensions:
$\text{Blended Score} = \frac{4 + 6 + 7 + 8 + 5 + 6 + 5 + 9 + 2 + 3}{10} = 5.5 / 10$
Note: This qualitative scorecard is intended solely for educational and informational purposes and does not constitute financial advice, nor does it represent an investment recommendation to buy, sell, or hold the security.
HIGHLY SPECULATIVE PROFILE
Verastem Oncology presents a classic high-risk, high-reward investment profile typical of late-stage biopharmaceutical companies.[26] The investment thesis is supported by two primary pillars: a growing commercial revenue stream from the AVMAPKI FAKZYNJA CO-PACK in recurrent LGSOC, and the clinical pipeline potential of VS-7375 in KRAS G12D-mutated solid tumors.[3, 5, 15]
The commercial launch of the CO-PACK in recurrent LGSOC provides a solid, growing revenue base.[5] Despite near-term quarterly volatility (such as the Q1 2026 revenue miss), the therapy's excellent clinical efficacy and 19.6-month median progression-free survival support steady long-term adoption among oncologists.[9, 21]
The clinical pipeline provides significant upside potential, led by the VS-7375 TARGET-D program.[5] VS-7375’s unique dual ON/OFF mechanism and excellent safety profile position it to compete in the KRAS G12D market, particularly following the clinical failure of competitor MRTX1133.[3, 17] Positive updated results from the RAMP 205 trial in frontline metastatic pancreatic cancer (showing an 86% overall survival rate at 6 months) further validate the therapeutic potential of Verastem's RAF/MEK and FAK combination strategy.[37, 38]
However, the risk profile remains elevated. The cash runway extends only into the first half of 2027, which means that Verastem will likely need to raise additional capital, leading to further near-term shareholder dilution.[5] Furthermore, the company’s long-term valuation is heavily dependent on binary clinical outcomes, particularly the Phase 3 RAMP 301 confirmatory trial in mid-2027.[5] A failure of RAMP 301 would likely trigger an FDA withdrawal of the CO-PACK, which would severely damage Verastem's core business model.[7]
Note: This report is based on historical and projected clinical and financial data, and is intended solely for educational and informational purposes. It does not constitute a recommendation to buy or sell securities, nor does it provide personalized investment or financial advice.
ASYMMETRIC BIOTECH BET
Verastem is currently trading at approximately $4.01, resting near its 50-day simple moving average of $3.88 but remaining below its 200-day simple moving average of $4.30.[29, 39] The relative strength index (RSI) stands at 53.4, indicating neutral price momentum, while the MACD indicator is flashing a mild buy signal.[39]
The short-term price outlook is consolidative as the market processes the company's recent Q1 2026 revenue miss.[21] Volatility is expected to remain high as investors monitor upcoming clinical updates from the TARGET-D 101 Phase 1/2 trial.[5]
Note: Technical analysis and short-term price targets are highly speculative, and past performance is not a guarantee of future results. This technical analysis is for informational purposes only and does not constitute financial advice.
CONSOLIDATIVE NEUTRAL TREND
View Verastem, Inc. (VSTM) stock page
Loading the interactive version of this report…